An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia

被引:3
|
作者
Li, Xue-Ying [1 ,2 ,3 ]
Qian, Jie-Jing [1 ,2 ,3 ]
Yang, Min [1 ,2 ,3 ]
Zhang, Yi [1 ,2 ,3 ]
Wang, Sha-Sha [1 ,2 ,3 ]
Meng, Hai-Tao [1 ,2 ,3 ]
Yu, Wen-Juan [1 ,2 ,3 ]
Tong, Hong-Yan [1 ,2 ,3 ]
Ye, Xiu-Jin [1 ,2 ,3 ]
Jin, Jie [1 ,2 ,3 ]
Zhu, Hong-Hu [1 ,2 ,3 ]
机构
[1] Zhejiang Univ, Affiliated Hosp 1, Coll Med, Dept Hematol, Hangzhou, Zhejiang, Peoples R China
[2] Zhejiang Univ, Zhejiang Prov Key Lab Hematol Oncol Diag & Treatm, Hangzhou, Zhejiang, Peoples R China
[3] Zhejiang Univ, Inst Hematol, Hangzhou, Zhejiang, Peoples R China
基金
中国国家自然科学基金;
关键词
IMATINIB; PHASE-2;
D O I
10.1111/bjh.16661
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:E231 / E234
页数:4
相关论文
共 50 条
  • [11] Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Foa, Robin
    Vitale, Antonella
    Vignetti, Marco
    Meloni, Giovanna
    Guarini, Anna
    De Propris, Maria Stefania
    Elia, Loredana
    Paoloni, Francesca
    Fazi, Paola
    Cimino, Giuseppe
    Nobile, Francesco
    Ferrara, Felicetto
    Castagnola, Carlo
    Sica, Simona
    Leoni, Pietro
    Zuffa, Eliana
    Fozza, Claudio
    Luppi, Mario
    Candoni, Anna
    Iacobucci, Ilaria
    Soverini, Simona
    Mandelli, Franco
    Martinelli, Giovanni
    Baccarani, Michele
    BLOOD, 2011, 118 (25) : 6521 - 6528
  • [12] A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens
    Xiong, Zhen-Yu
    Shen, Yao-Jia
    Zhang, Shi-Zhong
    Zhu, Hong-Hu
    HEMATOLOGY, 2024, 29 (01)
  • [13] A step ahead in Philadelphia chromosome-positive acute lymphoblastic leukaemia
    Ribera, Josep-Maria
    LANCET HAEMATOLOGY, 2018, 5 (12): : E602 - E603
  • [14] Chemotherapy-free regimen: a new hope in Philadelphia-positive acute lymphoblastic leukemia
    Saleh, Khalil
    Chahine, Claude
    Khalife, Nadine
    FUTURE ONCOLOGY, 2021, 17 (11) : 1265 - 1267
  • [15] Combination of arsenic trioxide and Dasatinib: a new strategy to treat Philadelphia chromosome-positive acute lymphoblastic leukaemia
    Wang, Tao
    Cheng, Chunyan
    Peng, Lijun
    Gao, Mengqing
    Xi, Mengping
    Rousseaux, Sophie
    Khochbin, Saadi
    Wang, Jin
    Mi, Jianqing
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2018, 22 (03) : 1614 - 1626
  • [16] Use of dasatinib in the patient with Philadelphia chromosome-positive acute lymphoblastic leukaemia with resistance to imatinib and renal failure
    Sonmez, M.
    Cobanoglu, U.
    Ovali, E.
    Omay, S. B.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2008, 33 (03) : 329 - 330
  • [17] Treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
    Ryuzo Ohno
    Current Oncology Reports, 2008, 10
  • [18] Treatment of Adult Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Ohno, Ryuzo
    CURRENT ONCOLOGY REPORTS, 2008, 10 (05) : 379 - 387
  • [19] A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
    Short, Nicholas James
    Kantarjian, Hagop M.
    Konopleva, Marina
    Bravo, Guillermo Montalban
    Ravandi, Farhad
    Jain, Nitin
    Kadia, Tapan M.
    Valero, Yesid Alvarado
    Chien, Kelly Sharon
    Daver, Naval Guastad
    Macaron, Walid
    Sasaki, Koji
    Thankachan, Jennifer
    Delumpa, Ricardo
    Mayor, Ejiroghene
    Deen, Wuliamatu
    Loiselle, Christopher
    Kwari, Monica
    Garris, Rebecca
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [20] Treatment of Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia-From Intensive Chemotherapy Combinations to Chemotherapy-Free Regimens A Review
    Jabbour, Elias
    Haddad, Fadi G.
    Short, Nicholas J.
    Kantarjian, Hagop
    JAMA ONCOLOGY, 2022, 8 (09) : 1340 - 1348